MediciNova’s Experimental ALS Therapy Found to be Safe in Clinical Trial

Biopharmaceutical company MediciNova, Inc. recently announced in a press release that the initial results of an ongoing clinical trial for the drug MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) were presented by the study’s principal investigator Dr. Benjamin Rix Brooks at the 2015 American Academy of Neurology (AAN)…

To better understand amyotrophic lateral sclerosis (ALS), a research team at Johns Hopkins Medicine was able to transform skin cells from ALS and Lou Gehrig’s disease patients into brain cells affected by this severe condition. The researchers deposited the human-made cells derived from the study into the first…

Researchers from the Institute of Pathobiochemistry at the Medical Center of Johannes Gutenberg University Mainz, Germany, have recently released results from a study in which they used animal experiments to assess the possibility that low-frequency alternating magnetic fields (LFMF), such as those generated by overhead power lines, are a…

It makes sense that when healthcare providers work together, better outcomes can result for people with amyotrophic lateral sclerosis (ALS). A new study supports this idea by showing that coordinated networks of care for ALS can result in fewer trips to the hospital, less deterioration and an expanded lifespan. The study, titled…